Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania

The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment. This retrospective cohort study evaluated the long-term virologic outcomes and safety of transitioning from an efavirenz-based regimen (tenofovir, lamivudin...

Full description

Saved in:
Bibliographic Details
Published in:AIDS research and therapy 2024-12, Vol.21 (1), p.98-6, Article 98
Main Authors: Majula, Revocatus T, Mweya, Clement N
Format: Article
Language:English
Subjects:
Adult
AIDS treatment
Alkynes
Anti-HIV agents
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiviral agents
Benzoxazines - adverse effects
Benzoxazines - therapeutic use
Biological products industry
Complications and side effects
Cyclopropanes
Dolutagravir-based antiretroviral therapy
Dosage and administration
Drug therapy
Efavirenz
Efavirenz-based antiretroviral therapy
Female
Heterocyclic Compounds, 3-Ring - adverse effects
Heterocyclic Compounds, 3-Ring - therapeutic use
Highly active antiretroviral therapy
HIV (Viruses)
HIV Infections - drug therapy
HIV-1 - drug effects
HIV-infected study participants
Humans
Lamivudine - therapeutic use
Male
Medical records
Middle Aged
Oxazines - therapeutic use
Patient compliance
Patient outcomes
Pharmacology, Experimental
Physiological aspects
Piperazines - therapeutic use
Pyridones - therapeutic use
Retrospective evaluation
Retrospective Studies
Tanzania
Tenofovir - therapeutic use
Treatment Outcome
Treatment outcomes
Viral Load - drug effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment. This retrospective cohort study evaluated the long-term virologic outcomes and safety of transitioning from an efavirenz-based regimen (tenofovir, lamivudine, efavirenz [TLE]) to a dolutegravir-based regimen (tenofovir, lamivudine, dolutegravir [TLD]) among adult HIV participants in Mbeya, Tanzania. Medical records of 250 adult HIV participants who transitioned from TLE to TLD at Mbeya Zonal Referral Hospital were reviewed from August 2022 to December 2022. The primary outcome was virologic failure, defined as HIV RNA > 1000 copies/mL. Secondary outcomes included viral suppression (
ISSN:1742-6405
1742-6405
DOI:10.1186/s12981-024-00662-z